An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
NCT02224573 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 681
Last updated 2022-02-03
Summary
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes.
Conditions
- Epilepsy
- Dravet Syndrome
- Lennox-Gastaut Syndrome
Interventions
- DRUG
-
GWP42003-P
Sponsors & Collaborators
-
GW Research Ltd
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-06-11
- Primary Completion
- 2020-09-24
- Completion
- 2020-09-24
More Related Trials
-
Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use)
NCT03676049 ·Status: AVAILABLE
-
Study of Cannabidiol for Drug-Resistant Epilepsies
NCT03014440 ·Status: NO_LONGER_AVAILABLE
-
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
NCT07233239 ·Status: RECRUITING ·Phase: PHASE1
-
Epidiolex and Drug Resistant Epilepsy in Children
NCT02397863 ·Status: AVAILABLE
-
Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy
NCT05803434 ·Status: UNKNOWN ·Phase: PHASE2
-
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
NCT04133480 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
NCT02544763 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
NCT05288283 ·Status: TERMINATED ·Phase: PHASE3
-
Cannabis Extract in Refractory Epilepsy Study
NCT03808935 ·Status: TERMINATED ·Phase: PHASE3
-
Cannabidiol in Children With Refractory Epileptic Encephalopathy
NCT03024827 ·Status: UNKNOWN ·Phase: PHASE1
-
Expanded Use of Cannabidiol Oral Solution
NCT03196934 ·Status: NO_LONGER_AVAILABLE
-
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
NCT02318537 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex
NCT06924827 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy
NCT02660255 ·Status: APPROVED_FOR_MARKETING
-
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
NCT02318602 ·Status: COMPLETED ·Phase: PHASE3
-
Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders
NCT02324673 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome
NCT06738732 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome
NCT04611438 ·Status: UNKNOWN ·Phase: PHASE3
-
CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children
NCT07023744 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
NCT02564952 ·Status: COMPLETED ·Phase: PHASE2
-
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
NCT03355300 ·Status: TERMINATED ·Phase: PHASE2
-
Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
NCT03336242 ·Status: TERMINATED ·Phase: PHASE2
-
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617 ·Status: RECRUITING ·Phase: PHASE3
-
The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy
NCT02523183 ·Status: UNKNOWN
-
Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy
NCT06523725 ·Status: WITHDRAWN ·Phase: PHASE2